GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vertex Pharmaceuticals Inc (XSWX:VRTX) » Definitions » Cyclically Adjusted Book per Share

Vertex Pharmaceuticals (XSWX:VRTX) Cyclically Adjusted Book per Share : CHF0.00 (As of Dec. 2023)


View and export this data going back to 2014. Start your Free Trial

What is Vertex Pharmaceuticals Cyclically Adjusted Book per Share?

Note: As Cyclically Adjusted Book per Share is a main component used to calculate Cyclically Adjusted PB Ratio. If the month end stock price for this stock is zero, result may not be accurate due to the exchange rate between different shares and the data will not be stored into our database. Selected historical data showed in the calculation section below is only for demostration purpose.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Vertex Pharmaceuticals's adjusted book value per share for the three months ended in Dec. 2023 was CHF59.307. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is CHF0.00 for the trailing ten years ended in Dec. 2023.

During the past 12 months, Vertex Pharmaceuticals's average Cyclically Adjusted Book Growth Rate was 32.30% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was 37.20% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was 36.60% per year. During the past 10 years, the average Cyclically Adjusted Book Growth Rate was 23.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Vertex Pharmaceuticals was 38.60% per year. The lowest was -7.70% per year. And the median was 5.45% per year.

As of today (2024-05-06), Vertex Pharmaceuticals's current stock price is CHF170.61. Vertex Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2023 was CHF0.00. Vertex Pharmaceuticals's Cyclically Adjusted PB Ratio of today is .

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Vertex Pharmaceuticals was 39.61. The lowest was 13.87. And the median was 25.13.


Vertex Pharmaceuticals Cyclically Adjusted Book per Share Historical Data

The historical data trend for Vertex Pharmaceuticals's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vertex Pharmaceuticals Cyclically Adjusted Book per Share Chart

Vertex Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Vertex Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Vertex Pharmaceuticals's Cyclically Adjusted Book per Share

For the Biotechnology subindustry, Vertex Pharmaceuticals's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vertex Pharmaceuticals's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vertex Pharmaceuticals's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Vertex Pharmaceuticals's Cyclically Adjusted PB Ratio falls into.



Vertex Pharmaceuticals Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Vertex Pharmaceuticals's adjusted Book Value per Share data for the three months ended in Dec. 2023 was:

Adj_Book= Book Value per Share /CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=59.307/129.4194*129.4194
=59.307

Current CPI (Dec. 2023) = 129.4194.

Vertex Pharmaceuticals Quarterly Data

Book Value per Share CPI Adj_Book
201403 4.588 99.695 5.956
201406 4.425 100.560 5.695
201409 4.508 100.428 5.809
201412 4.337 99.070 5.666
201503 3.928 99.621 5.103
201506 3.414 100.684 4.388
201509 3.651 100.392 4.707
201512 3.798 99.792 4.926
201603 3.797 100.470 4.891
201606 3.841 101.688 4.888
201609 4.008 101.861 5.092
201612 4.748 101.863 6.032
201703 6.036 102.862 7.594
201706 6.452 103.349 8.080
201709 6.822 104.136 8.478
201712 7.906 104.011 9.837
201803 8.931 105.290 10.978
201806 10.434 106.317 12.701
201809 11.009 106.507 13.377
201812 17.240 105.998 21.049
201903 18.434 107.251 22.244
201906 19.540 108.070 23.400
201909 20.300 108.329 24.252
201912 23.325 108.420 27.843
202003 24.180 108.902 28.736
202006 27.903 108.767 33.201
202009 29.028 109.815 34.210
202012 30.105 109.897 35.453
202103 32.572 111.754 37.721
202106 32.567 114.631 36.768
202109 34.308 115.734 38.365
202112 36.287 117.630 39.924
202203 39.543 121.301 42.190
202206 45.164 125.017 46.754
202209 49.470 125.227 51.126
202212 50.560 125.222 52.255
202303 52.105 127.348 52.953
202306 54.337 128.729 54.629
202309 57.948 129.860 57.752
202312 59.307 129.419 59.307

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.


Vertex Pharmaceuticals  (XSWX:VRTX) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Vertex Pharmaceuticals was 39.61. The lowest was 13.87. And the median was 25.13.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Vertex Pharmaceuticals Cyclically Adjusted Book per Share Related Terms

Thank you for viewing the detailed overview of Vertex Pharmaceuticals's Cyclically Adjusted Book per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Vertex Pharmaceuticals (XSWX:VRTX) Business Description

Address
50 Northern Avenue, Boston, MA, USA, 02210
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.